Back to top

Analyst Blog

BioMarin Pharmaceutical Inc. (BMRN - Analyst Report) recently acquired privately held biotechnology company, Zacharon Pharmaceuticals, which develops small molecules targeting pathways of glycan and glycolipid metabolism.

BioMarin bought 100% of Zacharon's share capital for $10 million upfront and might make additional clinical, regulatory and commercial milestone payments. Zacharon’s pipeline consists of two optimization programs -- inhibition of heparan sulfate synthesis for MPS III (mucopolysaccharidosis) and other MPS disorders, and inhibition of ganglioside synthesis for diseases like Tay Sachs and Sandhoff.

We expect the Zacharon acquisition to expand BioMarin’s drug development programs. BioMarin has a robust pipeline with several data readouts expected in the first half of 2013. In Nov 2012, the company reported positive results on its lead pipeline candidate, GALNS, indicated for the treatment of MPS IVA or morquio syndrome.

The company intends to seek regulatory approval for the candidate soon. BioMarin also expects GALNS to be approved in the US in the fourth quarter of 2013.

Another important candidate, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), is being developed for the treatment of phenylketonuria (PKU). In Sept 2012, the company presented positive preliminary results from a phase II program of PEG-PAL and expects to commence a phase III study on the candidate in the second quarter of 2013.

In addition to these late-stage candidates, the company has BMN-673 for (genetically defined cancers and advanced hematological malignancies) and BMN-701 (Pompe’s disease).  

Our Recommendation

We have a long-term Neutral recommendation on BioMarin. The stock carries a Zacks Rank #3 (Hold). However, other pharma stocks such as Agenus Inc. (AGEN - Snapshot Report) and Cambrex Corporation (CBM - Snapshot Report) carry a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.80 +7.04%
SIGNET JEWE… SIG 115.07 +6.13%
BANCO DO BR… BDORY 14.74 +5.66%
TRAVELCENTE… TA 11.66 +4.76%
AIR INDUSTR… AIRI 9.99 +4.15%